Cargando…
Health state utilities for metastatic breast cancer in Taiwan
BACKGROUND: New developments in medications for metastatic breast cancer (MBC) can be of great benefit to patients, but unfortunately these medicines also increase expenditures. Cost-utility analyses (CUAs) are needed to allocate health resources properly, and health utility values are required to c...
Autores principales: | Chou, Tzu-Chun, Chiang, Shao-Chin, Ko, Yu |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7377330/ https://www.ncbi.nlm.nih.gov/pubmed/32213442 http://dx.doi.org/10.1016/j.breast.2020.03.001 |
Ejemplares similares
-
Effectiveness and healthcare costs of eribulin versus capecitabine among metastatic breast cancer patients in Taiwan
por: Lin, Yu-Ju, et al.
Publicado: (2021) -
Health state utilities for metastatic breast cancer
por: Lloyd, A, et al.
Publicado: (2006) -
Health Utilities in Patients with Type 2 Diabetes in Taiwan
por: Chen, Chia-Chia, et al.
Publicado: (2021) -
An evaluation of the healthcare costs of metastatic breast cancer: A retrospective matched cohort study
por: Chen, Hsuan-Ming, et al.
Publicado: (2021) -
The status of hospital dentistry in Taiwan in October 2019
por: Cheng, Feng-Chou, et al.
Publicado: (2020)